Previous studies indicated that CMTM3 was silenced or down-regulated in gastric, breast, nasopharyngeal, esophageal, colon and renal carcinomas and its expression inversely correlates with grade and phase in prostate cancer when combined with IL30 study 23-25. The gene discussed is CMTM3; the disease is prostate cancer.